Efficacy, effects and indications of Dacomitinib/Dozerun

Dacomitinib/Dacomitinib (Dacomitinib) is an irreversible EGFR tyrosine kinase inhibitor (EGFR-TKI), mainly used for patients with non-small cell lung cancer (NSCLC) carrying EGFR sensitive mutations. EGFR mutations have a high incidence in lung adenocarcinoma. Such mutations can lead to abnormal proliferation and growth of tumor cells and have become an important target for precision treatment of lung cancer. Dacomitinib irreversibly binds to the EGFR receptor and blocks downstream signaling, thereby inhibiting tumor cell proliferation, inducing apoptosis, and delaying disease progression.

Compared with the first-generation EGFR inhibitorsDacomitinib is a second-generation irreversible inhibitor that has high affinity for common EGFR-sensitive mutations such as exon 19 deletion and L858R point mutation, and can also overcome treatment failure caused by some drug-resistant mutations to a certain extent. This gives it a clear advantage in the first-line treatment of patients with advanced NSCLC of specific genotypes. Dacomitinib's broad-spectrum inhibitory ability can cover EGFR-1, EGFR-2 and some drug-resistant mutations, thereby providing patients with more sustained and stable disease control.

In terms of clinical application, Duozerun is suitable for patients with locally advanced or metastatic non-small cell lung cancer, especially patients with gene mutation positive who have not receivedEGFR-TKI treatment. Oral administration facilitates long-term treatment, allowing patients to complete the course of treatment at home without the need for frequent hospitalization or intravenous infusions, which also reflects the convenience and quality of life advantages of targeted therapy. In addition, dacomitinib has shown potential advantages in disease control, prolongation of progression-free survival and maintenance of quality of life, providing a more personalized and precise treatment plan for patients with advanced NSCLC.

In general, dacomitinib provides an effective targeted treatment option for patients with EGFR-positive NSCLC through its irreversible EGFR inhibitory properties and mechanism of action. It is an important innovative drug in the field of targeted treatment of lung cancer, especially for first-line treatment and patients with specific drug-resistant mutations. It has clinical significance.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro